Idenix Pharmaceuticals has cleared successes from its development board and is pushing forward with later stages of a phase II HIV medication.

Idenix Pharmaceuticals has cleared its successes off the development board and is now ready to bring its next development products closer to market. In the past year, the company has been able to pass along its successful Tyzeka/Sebivo product to Novartis, the company’s collaboration partner, freeing capital and marketing expense.

The passing along of product expenses, expected to save the company approximately $45 million, has also enabled the company to pair human resources costs and focus on development of new products currently in the pipeline while reaping healthy residual rewards from product sales.

Idenix Pharmaceuticals cash position stands at approximately $100 million as it winds down 2008. New products are currently in Phase I and Phase II stages of development. The Phase II product, directed at HIV, has recently completed single dose and multi-dose 7 day trials for healthy individuals. The company has submitted, and expects to offer, findings at the Conference on Retroviruses and Opportunistic Infections in February 2008.

Idenix Pharmaceuticals is a research based development company. One of its largest strengths, past its development capabilities, is its association with a known company (Novartis) that can take its products and give them the marketing and production strengths they deserve.

Let us hear your thoughts below: